Part II: α-synuclein and its molecular pathophysiological role in neurodegenerative disease

Neuropharmacology

Volumn 45, Issue 1, 2003, Pages 14-44

  Dev, Kumlesh K ^a   Hofele, Katja ^a   Barbieri, Samuel ^a   Buchman, Vladimir L ^b   Van Der Putten, Herman ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Alzheimer's disease; Lewy bodies; Neurodegeneration; Parkinson's disease; Synuclein; Synucleinopathies

Indexed keywords

ALPHA SYNUCLEIN; DOPAMINE; GELDANAMYCIN; OLIGOMER; PROTEIN SERINE THREONINE KINASE; PROTEIN TYROSINE KINASE; TYROSINE;

AMINO ACID SEQUENCE; CELL CULTURE; CELL TYPE; CYTOTOXICITY; DEGENERATIVE DISEASE; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE MODEL; DOPAMINERGIC NERVE CELL; FLY; GENE EXPRESSION; GENE FUNCTION; GENE MUTATION; GENE SEQUENCE; GENE STRUCTURE; GLIA CELL; HUMAN; LEWY BODY; MOLECULAR DYNAMICS; MOLECULAR MECHANICS; MOLECULAR MODEL; MULTIGENE FAMILY; NERVE CELL; NONHUMAN; OXIDATION; OXIDATIVE STRESS; PARKINSON DISEASE; PATHOPHYSIOLOGY; PHOSPHORYLATION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN CONFORMATION; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN FOLDING; PROTEIN FUNCTION; PROTEIN GLYCOSYLATION; PROTEIN LOCALIZATION; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; SEQUENCE ANALYSIS; SHORT SURVEY; SPECIES DIFFERENCE; STRUCTURE ANALYSIS; TRANSGENE; TRANSGENIC ANIMAL;

EID: 0038460184     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0028-3908(03)00140-0     Document Type: Short Survey

References (403)

1. Abbas N., Lucking C.B., Ricard S., Durr A., Bonifati V., De M.G., et al. A wide variety of mutations in the parkin gene are responsible for autosomal recessive parkinsonism in Europe. French Parkinson's Disease Genetics Study Group and the European Consortium on Genetic Susceptibility in Parkinson's Disease. Human Molecular Genetics. 8:1999;567-574.
2. Abeliovich A., Schmitz Y., Farinas I., Choi-Lundberg D., Ho W.H., Castillo P.E., et al. Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system. Neuron. 25:2000;239-252.
3. Adams J.P., Sweatt J.D. Molecular psychology: roles for the ERK MAP kinase cascade in memory. Annual Review of Pharmacology and Toxicology. 42:2002;135-163.
4. Ahn B.H., Rhim H., Kim S.Y., Sung Y.M., Lee M.Y., Choi J.Y., et al. alpha-Synuclein interacts with phospholipase D isozymes and inhibits pervanadate-induced phospholipase D activation in human embryonic kidney-293 cells. Journal of Biological Chemistry. 277:2002;12334-12342.
5. Alim M.A., Hossain M.S., Arima K., Takeda K., Izumiyama Y., Nakamura M., et al. Tubulin seeds alpha-synuclein fibril formation. Journal of Biological Chemistry. 277:2002;2112-2117.
6. Apaydin H., Ahlskog E., Parisi J.E., Boeve B.F., Dickson D.W. Parkinson disease neuropathology, later-developing dementia and loss of levadopa response. Archives of Neurology. 59:2002;102-112.
7. Ara J., Przedborski S., Naini A.B., Jackson-Lewis V., Trifiletti R.R., Horwitz J., et al. Inactivation of tyrosine hydroxylase by nitration following exposure to peroxynitrite and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Proceedings of the National Academy of Sciences of the United States of America. 95:1998;7659-7663.
8. Arai Y., Yamazaki M., Mori O., Muramatsu H., Asano G., Katayama Y. alpha-Synuclein-positive structures in cases with sporadic Alzheimer's disease: morphology and its relationship to tau aggregation. Brain Research. 888:2001;287-296.
9. Arima K., Hirai S., Sunohara N., Aoto K., Izumiyama Y., Ueda K., et al. Cellular co-localization of phosphorylated tau- and NACP/alpha-synuclein epitopes in Lewy bodies in sporadic Parkinson's disease and in dementia with Lewy bodies. Brain Research. 843:1999;53-61.
10. Arima K., Mizutani T., Alim M.A., Tonozuka-Uehara H., Izumiyama Y., Hirai S., et al. NACP/alpha-synuclein and tau constitute two distinctive subsets of filaments in the same neuronal inclusions in brains from a family of parkinsonism and dementia with Lewy bodies: double-immunolabeling fluorescence and electron microscopic studies. Acta Neuropathologica. 100:2000;115-121.
11. Auluck P.K., Chan H.Y., Trojanowski J.Q., Lee V.M., Bonini N.M. Chaperone suppression of alpha-synuclein toxicity in a Drosophila model for Parkinson's disease. Science. 295:2002;865-868.
12. Auluck P.V., Bonini N.M. Pharmacological prevention of Parkinson disease in Drosophila. Nature Medicine. 8:2002;1185-1186.
13. Baba M., Nakajo S., Tu P.H., Tomita T., Nakaya K., Lee V.M., et al. Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies. American Journal of Pathology. 152:1998;879-884.
14. Bahr B.A., Bendiske J. The neuropathogenic contributions of lysosomal dysfunction. Journal of Neurochemistry. 83:2002;481-489.
15. Bennett M.C., Bishop J.F., Leng Y., Chock P.B., Chase T.N., Mouradian M.M. Degradation of alpha-synuclein by proteasome. Journal of Biological Chemistry. 274:1999;33855-33858.
16. Barbieri S., Hofele K., Wiederhold K.H., Probst A., Mistl C., Danner S., et al. Mouse models of alpha-synucleinopathy and Lewy pathology. alpha-Synuclein expression in transgenic mice. Advances in Experimental Medicine and Biology. 487:2001;147-167.
17. Betarbet R., Sherer T.B., MacKenzie G., Garcia-Osuna M., Panov A.V., Greenamyre J.T. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nature Neuroscience. 3:2000;1301-1306.
18. Biere A.L., Wood S.J., Wypych J., Steavenson S., Jiang Y., Anafi D., et al. Parkinson's disease-associated alpha-synuclein is more fibrillogenic than beta- and gamma-synuclein and cannot cross-seed its homologs. Journal of Biological Chemistry. 275:2000;34574-34579.
19. Boeve B.F., Silber M.H., Ferman T.J., Lucas J.A., Parisi J.E. Association of REM sleep behavior disorder and neurodegenerative disease may reflect an underlying synucleinopathy. Movement Disorder. 16:2001;622-630.
20. Bonifati V., Rizzu P., van Baren M.J., Schaap O., Breedveld G.J., Krieger E., et al. Mutations in the DJ-1 gene associated with autosomal recessive early-onset Parkinsonism. Science. 299:2003;256-259.
21. Braak E., Braak H. Silver staining method for demonstrating Lewy bodies in Parkinson's disease and argyrophilic oligodendrocytes in multiple system atrophy. Journal of Neuroscience Methods. 87:1999;111-115.
22. Braak H., Braak E., Yilmazer D., de V.R., Jansen E.N., Bohl J., et al. Amygdala pathology in Parkinson's disease. Acta Neuropathologica (Berlin). 88:1994;493-500.
23. Braak H., Braak E., Yilmazer D., Schultz C., de V.R., Jansen E.N. Nigral and extranigral pathology in Parkinson's disease. Journal of Neural Transmission-Supplement. 46:1995;15-31.
24. Braak H., Braak E., Yilmazer D., de V.R., Jansen E.N., Bohl J. Pattern of brain destruction in Parkinson's and Alzheimer's diseases. Journal of Neural Transmission. 103:1996;455-490.
25. Braak H., Sandmann-Keil D., Gai W., Braak E. Extensive axonal Lewy neurites in Parkinson's disease: a novel pathological feature revealed by alpha-synuclein immunocytochemistry. Neuroscience Letters. 265:1999;67-69.
26. Braak H., Rub U., Sandmann-Keil D., Gai W.P., de V.R., Jansen S.E., et al. Parkinson's disease: affection of brain stem nuclei controlling premotor and motor neurons of the somatomotor system. Acta Neuropathologica (Berlin). 99:2000;489-495.
27. Braak H., Del Tredici T.K., Sandmann-Keil D., Rub U., Schultz C. Nerve cells expressing heat-shock proteins in Parkinson's disease. Acta Neuropathologica (Berlin). 102:2001;449-454.
28. Braak H., Tredici K.D., Rub U., de Vos R.A., Jansen Steur E.N., Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiology of Aging. 24:2003;197-211.
29. Brion J.P., Couck A.M. Cortical and brainstem-type Lewy bodies are immunoreactive for the cyclin-dependent kinase 5. American Journal of Pathology. 147:1995;1465-1476.
30. Brookes A.J., St Clair D. Synuclein proteins and Alzheimer's disease. Trends in Neurosciences. 17:1994;404-405.
31. Brooks A.I., Chadwick C.A., Gelbard H.A., Cory-Slechta D.A., Federoff H.J. Paraquat elicited neurobehavioral syndrome caused by dopaminergic neuron loss. Brain Research. 823:1999;1-10.
32. Bucciantini M., Giannoni E., Chiti F., Baroni F., Formigli L., Zurdo J., et al. Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases. Nature. 416:2002;507-511.
33. Burn D.J., Jaros E. Multiple system atrophy: cellular and molecular pathology. Molecular Pathology. 54:2001;419-426.
34. Bussell R.J., Eliezer D. Residual structure and dynamics in Parkinson's disease-associated mutants of alpha-synuclein. Journal of Biological Chemistry. 276:2001;45996-46003.
35. Carlsson A. Treatment of Parkinson's disease with L-DOPA. The early discovery phase, and comments on current problems. Journal of Neural Transmission. 109:2002;777-787.
36. Cadet J.L., Brannock C. Free radicals and the pathobiology of brain dopamine systems. Neurochemistry International. 32:1998;117-131.
37. Cabin D.E., Shimazu K., Murphy D., Cole N.B., Gottschalk W., McIIwain K.L., et al. Synaptic vesicle depletion correlates with attenuated synaptic responses to prolonged repetitive stimulation in mice lacking α-synuclein. Journal of Neuroscience. 22:2002;8797-8807.
38. Chandra, S., Chen, X., Rizo, J., Jahn, R., Südhof, T.C. A broken α-helix in folded α-synuclein. Journal of Biological Chemistry, 278, 15313-15318.
39. Chen P.E., Specht C.G., Morris R.G., Schoepfer R. Spatial learning is unimpaired in mice containing a deletion of the alpha-synuclein locus. European Journal of Neuroscience. 16:2002;154-158.
40. Chiba-Falek O., Nussbaum R.L. Effect of allelic variation at the NACP-Rep1 repeat upstream of the alpha-synuclein gene (SNCA) on transcription in a cell culture luciferase reporter system. Human Molecular Genetics. 10:2001;3101-3109.
41. Choi P., Golts N., Snyder H., Chong M., Petrucelli L., Hardy J., et al. Co-association of Parkin and α-synuclein. Neuroreport. 12:2001;2839-2843.
42. Chung K.K., Zhang Y., Lim K.L., Tanaka Y., Huang H., Gao J., et al. Parkin ubiquitinates the alpha-synuclein-interacting protein, synphilin-1: implications for Lewy-body formation in Parkinson disease. Nature Medicine. 7:2001;1144-1150.
43. Ciechanover A., Schwartz A.L. The ubiquitin-proteasome pathway: the complexity and myriad functions of proteins death. Proceedings of the National Academy of Sciences of the United States of America. 95:1998;2727-2730.
44. Clayton D.F., George J.M. The synucleins: a family of proteins involved in synaptic function, plasticity, neurodegeneration and disease. Trends in Neurosciences. 21:1998;249-254.
45. Cole N.B., Murphy D.D. The cell biology of alpha-synuclein: a sticky problem? Neuromolecular Medicine. 1:2002;95-109.
46. Cole R.N., Hart G.W. Cytosolic O-glycosylation is abundant in nerve terminals. Journal of Neurochemistry. 79:2001;1080-1089.
47. Coleman M.P., Perry V.H. Axon pathology in neurological disease: a neglected therapeutic target. Trends in Neurosciences. 25:2002;532-537.
48. Conway K.A., Harper J.D., Lansbury P.T. Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease. Nature Medicine. 4:1998;1318-1320.
49. Conway K.A., Harper J.D., Lansbury P.T.J. Fibrils formed in vitro from alpha-synuclein and two mutant forms linked to Parkinson's disease are typical amyloid. Biochemistry. 39:2000a;2552-2563.
50. Conway K.A., Lee S.J., Rochet J.C., Ding T.T., Williamson R.E., Lansbury P.T.J. Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy. Proceedings of the National Academy of Sciences of the United States of America. 97:2000b;571-576.
51. Conway K.A., Rochet J.C., Bieganski R.M., Lansbury P.T.J. Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct. Science. 294:2001;1346-1349.
52. Cookson M.R. Pathways to parkinsonism. Neuron. 37:2003;7-10.
53. Craig N.J., Duran A.M., Hawker K.L., Shiels P., Glencorse T.A., Campbell J.M., et al. A candidate gene for human neurodegenerative disorders: a rat PKC gamma mutation causes a Parkinsonian syndrome. Nature Neuroscience. 4:2001;1061-1062.
54. Crowther R.A., Jakes R., Spillantini M.G., Goedert M. Synthetic filaments assembled from C-terminally truncated alpha-synuclein. FEBS Letters. 436:1998;309-312.
55. Culvenor J.G., McLean C.A., Cutt S., Campbell B.C., Maher F., Jakala P., et al. Non-Abeta component of Alzheimer's disease amyloid (NAC) revisited. NAC and alpha-synuclein are not associated with Abeta amyloid. American Journal of Pathology. 155:1999;1173-1181.
56. Da Costa C.A., Ancolio K., Checler F. Wild-type but not Parkinson's disease-related ala-53 - > Thr mutant alpha-synuclein protects neuronal cells from apoptotic stimuli. Journal of Biological Chemistry. 275:2000;24065-24069.
57. Da Costa C.A., Paitel E., Vincent B., Checler F. alpha-Synuclein lowers p53-dependent apoptotic response in neuronal cells: abolishment by 6-hydroxydopamine and implication for Parkinson's disease. Journal of Biological Chemistry. 277:2002;50980-50984.
58. Dauer W.T., Kholodilov N.G., Vila M., Trillat A.-C., Goodchild R., Larsen K.E., et al. Resistance of alpha-synuclein null mice to the parkinsonian neurotoxin MPTP. Proceedings of the National Academy of Sciences of the United States of America. 99:2002;14524-14529.
59. Davidson W.S., Jonas A., Clayton D.F., George J.M. Stabilization of alpha-synuclein secondary structure upon binding to synthetic membranes. Journal of Biological Chemistry. 273:1998;9443-9449.
60. Del Tredici K., Rueb U., de Vos R.A.I., Bohl J.R.E., Braak H. Where does Parkinson disease begin in the brain. Journal of Neuropathology and Experimental Neurology. 61:2002;413-426.
61. Delwaide P.J., Pepin J.L., Maertens D.N. The audiospinal reaction in Parkinsonian patients reflects functional changes in reticular nuclei. Annals of Neurology. 33:1993;63-69.
62. Den Hartog W.A., Bethlem J. The distribution of Lewy bodies in the central and autonomic nervous systems in idiopathic paralysis agitans. Journal of Neurology Neurosurgery and Psychiatry. 23:1960;283-290.
63. Dev, K.K., van der Putten, H., Sommer, B., Rovelli, G., 2003. Part I: Parkin-associated proteins and Parkinson's disease. Neuropharmacology 45, this issue. PII:S0028-3908(02)00337-4.
64. Dickson D.W., Liu W.K., Ksiezak-Reding H., Yen S.H. Neuropathologic and molecular considerations. Advances in Neurology. 82:2000;9-27.
65. Dickson D.W. alpha-Synuclein and the Lewy body disorders. Current Opinions in Neurology. 14:2001;423-432.
66. Ding T.T., Lee S.J., Rochet J.C., Lansbury P.T.J. Annular alpha-synuclein protofibrils are produced when spherical protofibrils are incubated in solution or bound to brain-derived membranes. Biochemistry. 41:2002;10209-10217.
67. Djamgoz M.B., Hankins M.W., Hirano J., Archer S.N. Neurobiology of retinal dopamine in relation to degenerative states of the tissue. Vision Research. 37:1997;3509-3529.
68. Doskeland A.P., Flatmark T. Ubiquitination of soluble and membrane-bound tyrosine hydroxylase and degradation of the soluble form. European Journal of Biochemistry. 269:2002;1561-1569.
69. Dong Z., Ferger B., Feldon J., Bueler H. Overexpression of Parkinson's disease-associated alpha-synuclein A53T by recombinant adeno-associated virus in mice does not increase the vulnerability of dopaminergic neurons to MPTP. Journal of Neurobiology. 53:2002;1-10.
70. Dou F., Netzer W.J., Tanemura K., Li F., Hartl U., Takashima A., et al. Chaperones increase association of tau protein with microtubules. Proceedings of the National Academy of Sciences of the United States of America. 100:2003;721-726.
71. Duda J.E., Giasson B.I., Chen Q., Gur T.L., Hurtig H.I., Stern M.B., et al. Widespread nitration of pathological inclusions in neurodegenerative synucleinopathies. American Journal of Pathology. 157:2000;1439-1445.
72. Duda J.E., Giasson B.I., Mabon M.E., Miller D.C., Golbe L.I., Lee V.M., et al. Concurrence of alpha-synuclein and tau brain pathology in the Contursi kindred. Acta Neuropathologica (Berlin). 104:2002a;7-11.
73. Duda J.E., Giasson B.I., Mabon M.E., Miller D.C., Golbe L.I., Lee V.M., et al. Novel antibodies to synuclein show abundant striatal pathology in Lewy body diseases. Annals of Neurology. 52:2002b;205-210.
74. Edwards E., Kitt C., Olives E., Finkelstein J., Wagster M., McDonald W.M. Depression and Parkinson's disease: a new look at an old probem. Depression Anxiety. 16:2002;39-48.
75. Eiserich J.P., Estevez A.G., Bamberg T.V., Ye Y.Z., Chumley P.H., Beckman J.S., et al. Microtubule dysfunction by posttranslational nitrotyrosination of alpha-tubulin: a nitric oxide-dependent mechanism of cellular injury. Proceedings of the National Academy of Sciences of the United States of America. 96:1999;6365-6370.
76. El-Agnaf O.M., Jakes R., Curran M.D., Wallace A. Effects of the mutations Ala30 to Pro and Ala53 to Thr on the physical and morphological properties of alpha-synuclein protein implicated in Parkinson's disease. FEBS Letters. 440:1998;67-70.
77. El-Agnaf O.M., Irvine G.B. Review: formation and properties of amyloid-like fibrils derived from alpha-synuclein and related proteins. Journal of Structural Biology. 130:2000;300-309.
78. El-Agnaf O.M.A., Irvine G.B. Aggregation and neurotoxicity of α-synuclein and related peptides. Biochemical Society Transactions. 30:2002;559-565.
79. Eliezer D., Kutluay E., Bussell R., Browne G. Conformational properties of alpha-synuclein in its free and lipid-associated states. Journal of Molecular Biology. 307:2001;1061-1073.
80. Elkon H., Don J., Melamed E., Ziv I., Shirvan A., Offen D. Mutant and wild-type alpha-synuclein interact with mitochondrial cytochrome C oxidase. Journal of Molecular Neuroscience. 18:2002;229-238.
81. Ellis C.E., Schwartzberg P.L., Grider T.L., Fink D.W., Nussbaum R.L. alpha-Synuclein is phosphorylated by members of the Src family of protein tyrosine kinases. Journal of Biological Chemistry. 276:2001;3879-3894.
82. Engelender S., Kaminsky Z., Guo X., Sharp A.H., Amaravi R.K., Kleiderlein J.J., et al. Synphilin-1 associates with alpha-synuclein and promotes the formation of cytosolic inclusions. Nature Genetics. 22:1999;110-114.
83. Falkenburger B.H., Barstow K.L., Mintz I.M. Dendrodendritic inhibition through reversal of dopamine transport. Science. 293:2001;2465-2470.
84. Farrer M., Gwinn-Hardy K., Hutton M., Hardy J. The genetics of disorders with synuclein pathology and parkinsonism. Human Molecular Genetics. 8:1999;1901-1905.
85. Farrer M., Maraganore D.M., Lockhart P., Singleton A., Lesnick T.G., de A.M., et al. alpha-Synuclein gene haplotypes are associated with Parkinson's disease. Human Molecular Genetics. 10:(17):2001a;1847-1851.
86. Farrer M., Chan P., Chen R., Tan L., Lincoln S., Hernandez D., et al. Lewy bodies and Parkinsonism in families with parkin mutations. Annals of Neurology. 50:2001b;293-300.
87. Ferl R.J., Manak M.S., Reyes M.F. The 14-3-3s. Genome Biology. 3:2002;3010.
88. Feany M.B., Bender W.W. A Drosophila model of Parkinson's disease. Nature. 404:2000;394-398. (See comments).
89. Forman M.S., Schmidt M.L., Kasturi S., Perl D.P., Lee V.M., Trojanowski J.Q. Tau and alpha-synuclein pathology in amygdala of Parkinsonism-dementia complex patients of Guam. American Journal of Pathology. 160:2002;1725-1731.
90. Forno L.S. Neuropathology of Parkinson's disease. Journal of Neuropathology and Experimental Neurology. 55:1996;259-272.
91. Fujiwara H., Hasegawa M., Dohmae N., Kawashima A., Masliah E., Goldberg M.S., et al. alpha-Synuclein is phosphorylated in synucleinopathy lesions. Nature Cell Biology. 4:2002;160-164.
92. Gai W.P., Blessing W.W., Blumbergs P.C. Ubiquitin-positive degenerating neurites in the brainstem in Parkinson's disease. Brain. 118:(Pt.6):1995;1447-1459.
93. George J.M. The synucleins. Genome Biology. 3:2001;3002.
94. Galvin J.E., Lee V.M., Trojanowski J.Q. Synucleinopathies: clinical and pathological implications. Archives of Neurology. 58:2001;186-190.
95. Gasser T. Genetics of Parkinson's disease. Clinical Genetics. 54:1998;259-265.
96. Geetha T., Wooten M.W. Structure and functional properties of the ubiquitin binding protein p62. FEBS Letters. 512:2002;19-24.
97. Ghee M., Fournier A., Mallet J. Rat alpha-synuclein interacts with Tat binding protein 1, a component of the 26S proteasomal complex. Journal of Neurochemistry. 75:2000;2221-2224.
98. Giasson B.I., Uryu K., Trojanowski J.Q., Lee V.M. Mutant and wild type human alpha-synucleins assemble into elongated filaments with distinct morphologies in vitro. Journal of Biological Chemistry. 274:1999;7619-7622.
99. Giasson B.I., Duda J.E., Murray I.V., Chen Q., Souza J.M., Hurtig H.I., et al. Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. Science. 290:2000a;985-989.
100. Giasson B.I., Jakes R., Goedert M., Duda J.E., Leight S., Trojanowski J.Q., et al. A panel of epitope-specific antibodies detects protein domains distributed throughout human alpha-synuclein in Lewy bodies of Parkinson's disease. Journal of Neuroscience Research. 59:2000b;528-533.
101. Giasson B.I., Murray I.V., Trojanowski J.Q., Lee V.M. A hydrophobic stretch of 12 amino acid residues in the middle of alpha-synuclein is essential for filament assembly. Journal of Biological Chemistry. 276:2001;2380-2386.
102. Giasson B.I., Duda J.E., Quinn S.M., Zhang B., Trojanowski J.Q., Lee V.M. Neuronal alpha-synucleinopathy with severe movement disorder in mice expressing A53T human alpha-synuclein. Neuron. 34:2002;521-533.
103. Goedert M. The significance of tau and alpha-synuclein inclusions in neurodegenerative diseases. Current Opinion in Genetics and Development. 11:2001a;343-351.
104. Goedert M. alpha-Synuclein and neurodegenerative diseases. Nature Reviews Neuroscience. 2:2001b;492-501.
105. Golbe L.I., Ezquerra M., Spychala J.R., Johnson W.G., Stenroos E.S., Mark M.H., et al. The tau A0 allele in Parkinson's disease. Movement Disorder. 16:2001;442-447.
106. Goldberg M.S., Lansbury J.P. Is there a cause-and-effect relationship between alpha-synuclein fibrillization and Parkinson's disease? Nature Cell Biology. 2:2000;E115-E119.
107. Goldstein D.S., Holmes C., Li S.T., Bruce S., Metman L.V., Cannon R.O. Cardiac sympathetic denervation in Parkinson disease. Annals of Internal Medicine. 133:2000;338-347.
108. Gomez-Isla T., Irizarry M.C., Mariash A., Chueng B., Soto O., Schrump S., et al. Motor dysfunction and gliosis with preserved dopaminergic markers in human alpha-synuclein A30P transgenic mice. Neurobiology of Aging. 24:2003;245-258.
109. + increases alpha-synuclein expression and ERK/MAP-kinase phosphorylation in human neuroblastoma SH-SY5Y cells. Brain Research. 935:2002;32-39.
110. Gomez-Tortosa, E., Irizarry, M.C., Gómez-Isla, T., 2000a. Clinical and neuropathological correlates of dementia with Lewy bodies. In: Molecular Genetics of Dementia. Proceedings of the Ninth Meeting of the International Study Group on the Pharmacology of Memory Disorders associated with aging. Cambridge, MA, USA, pp. 17-23 (Anonymous).
111. Gomez-Tortosa E., Newell K., Irizarry M.C., Sanders J.L., Hyman B.T. alpha-Synuclein immunoreactivity in dementia with Lewy bodies: morphological staging and comparison with ubiquitin immunostaining. Acta Neuropathologica (Berlin). 99:2000b;352-357.
112. Gomez-Tortosa E., Gonzalo I., Newell K., Yebenes G., Vonsattel P., Hyman B.T. Patterns of protein nitration in dementia with Lewy bodies and striatonigral degeneration. Acta Neuropathologica (Berlin). 103:2002;495-500.
113. Gosavi N., Lee H.J., Lee J.S., Patel S., Lee S.J. Golgi fragmentation occurs in the cells with prefibrillar alpha-synuclein aggregates and precedes the formation of fibrillar inclusion. Journal of Biological Chemistry. 277:2002;48984-48992.
114. Grant S.G., O'Dell T.J., Karl K.A., Stein P.L., Soriano P., Kandel E.R. Impaired long-term potentiation, spatial learning, and hippocampal development in fyn mutant mice. Science. 258:1992;1903-1910.
115. Green J., McDonald W.M., Vitek J.L., Evatt M., Freeman A., Haber M., Bakay R.A., Triche S., Sirockman B., De Long M.R. Cognitive impairments in advanced PD without dementia. Neurology. 59:2002;1320-1324.
116. Greenfield J.G., Bosanquet F.D. The brain-stem lesions in Parkinsonism. Journal of Neurology Neurosurgery and Psychiatry. 16:1953;213-226.
117. Gurd J.W. Protein tyrosine phosphorylation: implications for synaptic function. Neurochemistry International. 31:1997;635-649.
118. Gwinn-Hardy K.A., Crook R., Lincoln S., Adler C.H., Caviness J.N., Hardy J., et al. A kindred with Parkinson's disease not showing genetic linkage to established loci. Neurology. 54:2000;504-507.
119. Gwinn-Hardy K. Genetics of Parkinsonism. Movement Disorder. 17:2002;645-656.
120. Halliday G.M., Li Y.W., Blumbergs P.C., Joh T.H., Cotton R.G., Howe P.R., et al. Neuropathology of immunohistochemically identified brainstem neurons in Parkinson's disease. Annals of Neurology. 27:1990;373-385.
121. Hamilton R.L. Lewy bodies in Alzheimer's disease: a neuropathological review of 145 cases using alpha-synuclein immunohistochemistry. Brain Pathology. 10:2000;378-384.
122. Han H., Weinreb P.H., Lansbury P.T.J. The core Alzheimer's peptide NAC forms amyloid fibrils which seed and are seeded by beta-amyloid: is NAC a common trigger or target in neurodegenerative disease? Chemistry and Biology. 2:1995;163-169.
123. Harding A.J., Stimson E., Henderson J.M., Halliday G.M. Clinical correlates of selective pathology in the amygdala of patients with Parkinson's disease. Brain. 125:2002;2431-2445.
124. Hardy J., Gwinn-Hardy K. Neurodegenerative disease: a different view of diagnosis. Molecular Medicine Today. 5:1999;514-517.
125. Harper J.D., Wong S.S., Lieber C.M., Lansbury P.T. Observation of metastable Abeta amyloid protofibrils by atomic force microscopy. Chemistry and Biology. 4:1997a;119-125.
126. Harper J.D., Lieber C.M., Lansbury P.T.J. Atomic force microscopic imaging of seeded fibril formation and fibril branching by the Alzheimer's disease amyloid-beta protein. Chemistry and Biology. 4:1997b;951-959.
127. Harper J.D., Wong S.S., Lieber C.M., Lansbury P.T.J. Assembly of A beta amyloid protofibrils: an in vitro model for a possible early event in Alzheimer's disease. Biochemistry. 38:1999;8972-8980.
128. Hasegawa M., Fujiwara H., Nonaka T., Wakabayashi K., Takahashi H., Lee V.M.-Y., et al. Phosphorylated α-synuclein is ubiquitinated in α-synucleinopathy lesions. Journal of Biological Chemistry. 277:2002;49071-49076.
129. Hashimoto M., Hsu L.J., Sisk A., Xia Y., Takeda A., Sundsmo M., et al. Human recombinant NACP/alpha-synuclein is aggregated and fibrillated in vitro: relevance for Lewy body disease. Brain Research. 799:1998;301-306.
130. Hashimoto M., Yoshimoto M., Sisk A., Hsu L.J., Sundsmo M., Kittel A., et al. NACP, a synaptic protein involved in Alzheimer's disease, is differentially regulated during megakaryocyte differentiation. Biochemical and Biophysical Research Communications. 237:1997;611-616.
131. Hashimoto M., Takeda A., Hsu L.J., Takenouchi T., Masliah E. Role of cytochrome c as a stimulator of α-synuclein aggregation in Lewy body disease. Journal of Biological Chemistry. 274:1999;28849-28852.
132. Hashimoto M., Rockenstein E., Mante M., Mallory M., Masliah E. Masliah, E., beta-Synuclein inhibits alpha-synuclein aggregation: a possible role as an anti-parkinsonian factor. Neuron. 32:2001;213-223.
133. Hashimoto M., Hsu L.J., Rockenstein E., Takenouchi T., Mallory M., Masliah E. alpha-Synuclein protects against oxidative stress via inactivation of the c-Jun N-terminal kinase stress-signaling pathway in neuronal cells. Journal of Biological Chemistry. 277:2002;11465-11472.
134. Hicke L. Protein regulation by monoubiquitin. Nature Reviews Neuroscience. 2:2002;195-201.
135. Hedge A.N., DiAntonio A. Ubiquitin and the synapse. Nature Reviews Neuroscience. 3:2002;854-861.
136. Hishikawa N., Hashizume Y., Yoshida M., Sobue G. Widespread occurrence of argyrophilic glial inclusions in Parkinson's disease. Neuropathology and Applied Neurobiology. 27:2001;362-372.
137. Hsu L.J., Sagara Y., Arroyo A., Rockenstein E., Sisk A., Mallory M., et al. alpha-synuclein promotes mitochondrial deficit and oxidative stress. American Journal of Pathology. 157:2000;401-410.
138. Ihara, M., Tomimoto, H., Katiyama, H., Morioka, Y., Akiguchi, I., Shibasaki, H., Noda, M., Kinoshita, M., 2003. Association of the cytoskeletal GTP-binding protein Sept 4/5 with cytoplasmic inclusions found in Parkinson's disease and other synucleinopathies. Journal of Biological Chemistry, in press.
139. Ii K., Ito H., Tanaka K., Hirano A. Immunocytochemical co-localization of the proteasome in ubiquitinated structures in neurodegenerative diseases and the elderly. Journal of Neuropathology and Experimental Neurology. 56:1997;125-131.
140. Ince P. Dementia with Lewy bodies. Advances in Experimental Medicine and Biology. 487:2001;135-145.
141. Ince P.G., Perry E.K., Morris C.M. Dementia with Lewy bodies. A distinct non-Alzheimer dementia syndrome? Brain Pathology. 8:1998;299-324.
142. Ingram S.L., Prasad B.M., Amara S.G. Dopamine transporter-mediated conductances increase excitability of midbrain dopamine neurons. Nature Neuroscience. 5:2002;971-978.
143. Irizarry M.C., Growdon W., Gomez-Isla T., Newell K., George J.M., Clayton D.F., et al. Nigral and cortical Lewy bodies and dystrophic nigral neurites in Parkinson's disease and cortical Lewy body disease contain alpha-synuclein immunoreactivity. Journal of Neuropathology and Experimental Neurology. 57:1998;334-337.
144. Iseki E., Marui W., Kosaka K., Ueda K. Frequent coexistence of Lewy bodies and neurofibrillary tangles in the same neurons of patients with diffuse Lewy body disease. Neuroscience Letters. 265:1999;9-12.
145. Ishikawa A., Takahashi H. Clinical and neuropathological aspects of autosomal recessive juvenile arkinsonism. Journal of Neurology. 245:1998;4-9.
146. Ishizuka T., Satoh T., Monden T., Shibusawa N., Hashida T., Yamada M., et al. Human immunodeficiency virus type 1 Tat binding protein-1 is a transcriptional coactivator specific for TR. Molecular Endocrinology. 15:2001;1329-1343.
147. Iwanaga K., Wakabayashi K., Yoshimoto M., Tomita I., Satoh H., Takashima H., et al. Lewy body-type degeneration in cardiac plexus in Parkinson's and incidental Lewy body diseases. Neurology. 52:1999;1269-1271.
148. Iwata A., Miura S., Kanazawa I., Sawada M., Nukina N. alpha-Synuclein forms a complex with transcription factor Elk-1. Journal of Neurochemistry. 77:2001a;239-252.
149. Iwata A., Maruyama M., Kanazawa I., Nukina N. alpha-Synuclein affects the MAPK pathway and accelerates cell death. Journal of Biological Chemistry. 276:2001b;45320-45329.
150. Izumi Y., Morino H., Oda M., Maruyama H., Udaka F., Kameyama M., et al. Genetic studies in Parkinson's disease with an alpha-synuclein/NACP gene polymorphism in Japan. Neuroscience Letters. 300:2001;125-127.
151. Jaken S., Parker P.J. Protein kinase C binding partners. Bioessays. 22:2000;245-254.
152. Jellinger K.A. Pathology of Parkinson's disease. Changes other than the nigrostriatal pathway. Molecular and Chemical Neuropathology. 14:1991;153-197.
153. Jellinger K.A. Recent developments in the pathology of Parkinson's disease. Journal of Neural Transmission. 62:2003;347-376.
154. Jenco J.M., Rawlingson A., Daniels B., Morris A.J. Regulation of phospholipase D2: selective inhibition of mammalian phospholipase D isoenzymes by alpha- and beta-synucleins. Biochemistry. 37:1998;4901-4909.
155. Jensen P.H., Hojrup P., Hager H., Nielsen M.S., Jacobsen L., Olesen O.F., et al. Binding of Abeta to alpha- and beta-synucleins: identification of segments in alpha-synuclein/NAC precursor that bind Abeta and NAC. Biochemical Journal. 323:1997;539-546.
156. Jensen P.H., Nielsen M.S., Jakes R., Dotti C.G., Goedert M. Binding of alpha-synuclein to brain vesicles is abolished by familial Parkinson's disease mutation. Journal of Biological Chemistry. 273:1998;26292-26294.
157. Jensen P.H., Hager H., Nielsen M.S., Hojrup P., Gliemann J., Jakes R. alpha-Synuclein binds to Tau and stimulates the protein kinase A-catalyzed tau phosphorylation of serine residues 262 and 356. Journal of Biological Chemistry. 274:1999;25481-25489.
158. Jensen P.H., Islam K., Kenney J., Nielsen M.S., Power J., Gai W.P. Microtubule-associated protein 1B Is a component of cortical Lewy bodies and binds alpha-synuclein filaments. Journal of Biological Chemistry. 275:2000;21500-21507.
159. Jensen P.H., Gai W.P. alpha-Synuclein. Axonal transport, ligand interaction and neurodegeneration. Advances in Experimental Medicine and Biology. 487:2001;129-134.
160. Jo E., McLaurin J., Yip C.M., St George-Hyslop P., Fraser P.E. alpha-Synuclein membrane interactions and lipid specificity. Journal of Biological Chemistry. 275:2000;34328-34334.
161. Jo E., Fuller N., Rand R.P., St George-Hyslop P., Fraser P.E. Defective membrane interactions of familial Parkinson's disease mutant A30P alpha-synuclein. Journal of Molecular Biology. 315:2002;799-807.
162. Junn E., Mouradian M.M. Human alpha-synuclein over-expression increases intracellular reactive oxygen species levels and susceptibility to dopamine. Neuroscience Letters. 320:2002;146-150.
163. Junn E., Lee S.S., Suhr U.T., Mouradian M.M. Parkin accumulates in aggresomes due to protease impairment. Journal of Biological Chemistry. 277:2002;47870-47877.
164. Junn E., Ronchetti R.D., Quezado M.M., Kim S.-Y., Mouradian M.M. Tissue transglutaminase-induced aggregation of α-synuclein: implications for Lewy body formation in Parkinson's disease and dementia with Lewy bodies. Proceedings of the National Academy of Sciences of the United States of America. 100:2003;2047-2052.
165. Kahle P.J., Neumann M., Ozmen L. Physiology and pathophysiology of -synuclein: cell culture and transgenic animal models based on a Parkinson's disease-associated protein. Molecular Genetics of Dementia, Proceedings of the Ninth Meeting of the International Study Group on the Pharmacology of Memory Disorders Associated with Aging, Cambridge, MA, USA. 2000a.
166. Kahle P.J., Neumann M., Ozmen L., Muller V., Jacobsen H., Schindzielorz A., et al. Subcellular localization of wild-type and Parkinson's disease-associated mutant alpha-synuclein in human and transgenic mouse brain. Journal of Neuroscience. 20:2000b;6365-6373.
167. Kahle P.J., Neumann M., Ozman L., Muller V., Odoy S., Okamoto N., Jacobsen H., Iwatsubo T., Trojanowski J.Q., Takahashi H., Wakabayashi K., Bogdanovic N., Riederer P., Kretzschmar H.A., Haas C. Selective insolubility of alpha-synuclein in human Lewy body diseases is recapitulated in a transgenic mouse model. American Journal Pathology. 159:2001;2215-2225.
168. Kahle P.J., Neumann M., Ozmen L., Muller V., Jacobsen H., Spooren W., et al. Hyperphosphorylation and insolubility of alpha-synuclein in transgenic mouse oligodendrocytes. EMBO Reports. 3:2002a;583-588.
169. Kahle P.J., Haas C., Kretschmar H.A., Neumann M. Structure/function of alpha-synuclein in health and disease: rational development of animal models for Parkinson's and related diseases. Journal of Neurochemistry. 82:2002b;449-457.
170. Kakimura J., Kitamura Y., Takata K., Kohno Y., Nomura Y., Taniguchi T. Release and aggregation of cytochrome c and alpha-synuclein are inhibited by the antiparkinsonian drugs, talipexole and pramipexole. European Journal of Pharmacology. 417:2001;59-67.
171. Kalisz H.M., Erck C., Plessmann U., Wehland J. Incorporation of nitrotyrosine into alpha-tubulin by recombinant mammalian tubulin-tyrosine ligase. Biochimica et Biophysica Acta. 1481:2000;131-138.
172. Kanda S., Bishop J.F., Eglitis M.A., Yang Y., Mouradian M.M. Enhanced vulnerability to oxidative stress by alpha-synuclein mutations and C-terminal truncation. Neuroscience. 97:2000;279-284. (In process citation).
173. Kawamata H., McLean P.J., Sharma N., Hyman B.T. Interaction of alpha-synuclein and synphilin-1: effect of Parkinson's disease-associated mutations. Journal of Neurochemistry. 77:2001;929-934.
174. Kawamoto Y., Akiguchi I., Nakamura S., Honjyo Y., Shibasaki H., Budka H. 14-3-3 proteins in Lewy bodies in Parkinson disease and diffuse Lewy body disease brains. Journal of Neuropathology and Experimental Neurology. 61:2002a;245-253.
175. Kawamoto Y., Akiguchi I., Nakamura S., Budka H. Accumulation of 14-3-3 proteins in glial cytoplasmic inclusions in multiple system atrophy. Annals of Neurology. 52:2002b;722-731.
176. Kim J.H., Auerbach J.M., Rodriguez-Gomez J.A., Velasco I., Gavin D., Lumelsky N., et al. Dopamine neurons derived from embryonic stem cells function in an animal model of Parkinson's disease. Nature. 418:2002a;50-56.
177. Kim T.D., Paik S.R., Yang C.H., Kim J. Structural changes in alpha-synuclein affect its chaperone-like activity in vitro. Protein Science. 9:2000;2489-2496.
178. Kim Y.S., Lee D., Lee E.K., Sung J.Y., Chung K.C., Kim J., et al. Multiple ligand interaction of alpha-synuclein produced various forms of protein aggregates in the presence of Abeta25-35, copper, and eosin. Brain Research. 908:2001;93-98.
179. Kim T.D., Paik S.R., Yang C.H. Structural and functional implications of C-terminal regions of alpha-synuclein. Biochemistry. 41:2002b;13782-13790.
180. Kirik D., Rosenblad C., Burger C., Lundberg C., Johansen T.E., Muzyczka N., et al. Parkinson-like neurodegeneration induced by targeted overexpression of alpha-synuclein in the nigrostriatal system. Journal of Neuroscience. 22:2002;2780-2791.
181. Kirik D., Annett L.E., Burger C., Muzyczka N., Mandel R.J., Björklund A. Nigrostriatal α-synucleinopathy induced by viral vector-mediated overexpression of human α-synuclein: a new primate model of Parkinson's disease. Proceedings of the National Academy of Sciences of the United States of America. 100:2003;2884-2889.
182. Klein R.L., King M.A., Hamby M.E., Meyer E.M. Dopaminergic cell loss induced by human A30P alpha-synuclein gene transfer to the rat substantia nigra. Human Gene Therapy. 13:2002;605-612.
183. Ko L., Mehta N.D., Farrer M., Easson C., Hussey J., Yen S., et al. Sensitization of neuronal cells to oxidative stress with mutated human alpha-synuclein. Journal of Neurochemistry. 75:2000;2546-2554.
184. Kobayashi H., Kruger R., Markopoulou K., Wszolek Z., Chase B., Taka H., et al. Haploinsufficiency at the alpha-synuclein gene underlies phenotypic severity in familial Parkinson's disease. Brain. 126:2003;32-42.
185. Kotzbauer P.T., Trojanowsk J.Q., Lee V.M. Lewy body pathology in Alzheimer's disease. Journal of Molecular Neuroscience. 17:2001;225-232.
186. Kowall N.W., Hantraye P., Brouillet E., Beal M.F., McKee A.C., Ferrante R.J. MPTP induces alpha-synuclein aggregation in the substantia nigra of baboons. Neuroreport. 11:2000;211-213.
187. Krishnan S., Chi E.Y., Wood S.J., Kendrick B.S., Li C., Garzon-Rodriguez W., et al. Oxidative dimer formation is the critical rate-limiting step for Parkinson's disease α-synuclein fibrillogenesis. Biochemistry. 42:2003;829-837.
188. Kruger R., Kuhn W., Muller T., Woitalla D., Graeber M., Kosel S., et al. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease [letter]. Nature Genetics. 18:1998;106-108.
189. Kruger R., Vieira-Saecker A.M., Kuhn W., Berg D., Muller T., Kuhnl N., et al. Increased susceptibility to sporadic Parkinson's disease by a certain combined alpha-synuclein/apolipoprotein E genotype. Annals of Neurology. 45:1999;611-617.
190. Kruger R., Eberhardt O., Riess O., Schulz J.B., Riess O. Parkinson's disease: one biochemical pathway to fit all genes? Trends in Molecular Medicine. 8:2002;236-240.
191. Kurosinski P., Guggisberg M., Goetz J. Alzheimer's and Parkinson's disease - overlapping or synergistic pathologies? Trends in Molecular Medicine. 8:2002;3-5.
192. Kuusisto E., Salminen A., Alafuzoff I. Ubiquitin-binding protein p62 is present in neuronal and glial inclusions in human tauopathies and synucleinopathies. Neuroreport. 12:2001;2085-2090.
193. Kuusisto E., Salminen A., Alafuzoff I. Early accumulation of p62 in neurofibrillary tangles in Alzheimer's disease: possible role in tangle formation. Neuropathology and Applied Neurobiology. 28:2002;228-237.
194. Lam Y.A., Lawson T.G., Velayutham M., Zweier J.L., Pickart C.M. A proteasomal ATPase subunit recognizes the polyubuquitin degradation signal. Nature. 416:2002;763-767.
195. Lansbury P.T., Brice A. Genetics of Parkinson's disease and biochemical studies of implicated gene products. Current Opinion in Genetics and Development. 12:(3):2002;299-306.
196. Larsen C.N., Krantz B.A., Wilkinson K.D. Substrate specificity of deubiquitinating enzymes: ubiquitin C-terminal hydrolases. Biochemistry. 37:1998;3358-3368.
197. Lashuel H.A., Hartley D., Petre B.M., Walz T., Lansbury P.T.J. Neurodegenerative disease: amyloid pores from pathogenic mutations. Nature. 418:2002;291.
198. Lee G., Newman S.T., Gard D.L., Band H., Panchamoorthy G. Tau interacts with src-family non-receptor tyrosine kinases. Journal of Cell Science. 111:1998;3167-3177.
199. Lee M., Hyun D., Halliwell B., Jenner P. Effect of the overexpression of wild-type or mutant alpha-synuclein on cell susceptibility to insult. Journal of Neurochemistry. 76:2001;998-1009.
200. Lee H.J., Lee S.J. Characterization of cytoplasmic alpha-synuclein aggregates: fibril formation is tightly linked to the inclusion forming process in cells. Journal of Biological Chemistry. 277:2002;48976-48983.
201. Lee H.J., Shin S.Y., Choi C., Lee Y.H., Lee S.J. Formation and removal of alpha-synuclein aggregates in cells exposed to mitochondrial inhibitors. Journal of Biological Chemistry. 277:2002a;5411-5417.
202. Lee D., Lee S.Y., Lee E.N., Chang C.S., Paik S.R. alpha-Synuclein exhibits competitive interaction between calmodulin and synthetic membranes. Journal of Neurochemistry. 82:2002b;1007-1017.
203. Lee M.K., Stirling W., Xu Y., Xu X., Qui D., Mandir A.S., et al. Human alpha-synuclein-harboring familial Parkinson's disease-linked Ala-53 - > Thr mutation causes neurodegenerative disease with alpha-synuclein aggregation in transgenic mice. Proceedings of the National Academy of Sciences of the United States of America. 99:2002c;8968-8973.
204. + toxicity in vitro. Neuroreport. 13:2002;1279-1283.
205. Leroy E., Boyer R., Auburger G., Leube B., Ulm G., Mezey E., et al. The ubiquitin pathway in Parkinson's disease [letter]. Nature. 395:1998;451-452.
206. Li J., Uversky V.N., Fink A.L. Effect of familial Parkinson's disease point mutations A30P and A53T on the structural properties, aggregation, and fibrillation of human alpha-synuclein. Biochemistry. 40:2001;11604-11613.
207. Li J.Y., Henning J.P., Dahlstrom A. Differential localization of alpha-, beta- and gamma-synucleins in the rat CNS. Neuroscience. 113:2002;463-478.
208. Lippa C.F., Fujiwara H., Mann D.M., Giasson B., Baba M., Schmidt M.L., et al. Lewy bodies contain altered alpha-synuclein in brains of many familial Alzheimer's disease patients with mutations in pesenilin and amyloid precursor protein genes. American Journal of Pathology. 153:1998;1365-1370.
209. Lippa C.F., Schmidt M.L., Lee V.M., Trojanowski J.Q. Antibodies to alpha-synuclein detect Lewy bodies in many Down's syndrome brains with Alzheimer's disease. Annals of Neurology. 45:1999;353-357.
210. Lippa C.F., Schmidt M.L., Lee V.M., Trojanowski J.Q. alpha-Synuclein in familial Alzheimer disease: epitope mapping parallels dementia with Lewy bodies and Parkinson disease. Archives of Neurology. 58:2001;1817-1820.
211. Liu Y., Fallon L., Lashuel H.A., Liu Z., Lansbury P.T. The UCH-L1 gene encodes two opposing enzymatic activities that affect α-synuclein degradation and Parkinson's disease susceptibility. Cell. 111:2002;209-218.
212. Llinas R., Moreno H., Sugimori M., Mohammadi M., Schlessinger J. Differential pre- and postsynaptic modulation of chemical transmission in the squid giant synapse by tyrosine phosphorylation. Proceedings of the National Academy of Sciences of the United States of America. 94:1997;1990-1994.
213. Lo Bianco C., Ridet J.-L., Schneider B.L., Deglon N., Aebischer P. α-Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease. Proceedings of the National Academy of Sciences of the United States of America. 99:2002;10813-10818.
214. Lotharius J., Barg S., Wiekop P., Lundberg C., Raymon H.K., Brundin P. Effect of mutant alpha-synuclein on dopamine homeostasis in a new human mesencephalic cell line. Journal of Biological Chemistry. 277:2002;38884-38894.
215. Lotharius J., Brundin P. Impaired dopamine storage resulting from alpha-synuclein mutations may contribute to the pathogenesis of Parkinson's disease. Human Molecular Genetics. 11:2002a;2395-2407.
216. Lotharius J., Brundin P. Pathogenesis of Parkinson's disease: dopamine, vesicles and α-synuclein. Nature Reviews Neuroscience. 3:2002b;1-11.
217. Lowe J., McDermott H., Landon M., Mayer R.J., Wilkinson K.D. Ubiquitin carboxyl-terminal hydrolase (PGP 9.5) is selectively present in ubiquitinated inclusion bodies characteristic of human neurodegenerative diseases. Journal of Pathology. 161:1990;153-160.
218. Lucking C.B., Abbas N., Durr A., Bonifati V., Bonnet A.M., de B.T. Homozygous deletions in parkin gene in European and North African families with autosomal recessive juvenile parkinsonism. The European Consortium on genetic susceptibility in Parkinson's disease and the French Parkinson's Disease Genetics Study Group. Lancet. 352:1998;1355-1356.
219. Lucking C.B., Durr A., Bonifati V., Vaughan J., De M.G., Gasser T., et al. Association between early-onset Parkinson's disease and mutations in the parkin gene. French Parkinson's Disease Genetics Study Group. New England Journal of Medicine. 342:2000;1560-1567.
220. Lykkebo S., Jensen P.H. Alpha-Synuclein and presynaptic function: implications for Parkinson's disease. Neuromolecular Medicine. 2:2002;115-129.
221. Manning-Bog A.B., McCormack A.L., Li J., Uversky V.N., Fink A.L., Di M.D. The herbicide paraquat causes up-regulation and aggregation of alpha-synuclein in mice: paraquat and alpha-synuclein. Journal of Biological Chemistry. 277:2002;1641-1644.
222. Martin E.R., Scott W.K., Nance M.A., Watts R.L., Hubble J.P., Koller W.C., et al. Association of single-nucleotide polymorphisms of the tau gene with late-onset Parkinson disease. Journal of American Medical Association. 286:2002;2245-2250.
223. Martinez, J., Moeller, I., Erdjument-Bromage, H., Tempst, P., Lauring, B. Parkinson's disease associated α-synuclein is a calmodulin substrate. Journal of Biological Chemistry, in press.
224. Marui W., Iseki E., Ueda K., Kosaka K. Occurrence of human alpha-synuclein immunoreactive neurons with neurofibrillary tangle formation in the limbic areas of patients with Alzheimer's disease. Journal of Neurological Sciences. 174:2000;81-84.
225. Marui W., Iseki E., Nakai T., Miura S., Kato M., Ueda K., et al. Progression and staging of Lewy pathology in brains from patients with dementia with Lewy bodies. Journal of Neurological Sciences. 195:2002;153-159.
226. Masliah E., Rockenstein E., Veinbergs I., Mallory M., Hashimoto M., Takeda A., et al. Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders. Science. 287:2000;1265-1269.
227. Masliah E., Rockenstein E., Veinbergs I., Sagara Y., Mallory M., Hashimoto M., et al. beta-Amyloid peptides enhance alpha-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease. Proceedings of the National Academy of Sciences of the United States of America. 98:2001;12245-12250.
228. Matsuoka Y., Vila M., Lincoln S., McCormack A., Picciano M., LaFrancois J., et al. Lack of nigral pathology in transgenic mice expressing human alpha-synuclein driven by the tyrosine hydroxylase promoter. Neurobiology of Disease. 8:2002;535-539.
229. McKeith I., Del S.T., Spano P., Emre M., Wesnes K., Anand R., et al. Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet. 356:2000;2031-2036.
230. McKeith I.G. Clinical Lewy body syndromes. Annals of the New York Academy of Sciences. 920:2000;1-8.
231. McLean P.J., Ribich S., Hyman B.T. Subcellular localization of alpha-synuclein in primary neuronal cultures: effect of missense mutations. Journal of Neural Transmission-Supplement (58). 2000;53-63.
232. McLean P.J., Kawamata H., Hyman B.T. alpha-Synuclein-enhanced green fluorescent protein fusion proteins form proteasome sensitive inclusions in primary neurons. Neuroscience. 104:2001;901-912.
233. McLean P.J., Hyman B.T. An alternatively spliced form of rodent alpha-synuclein forms intracellular inclusions in vitro: role of the carboxy-terminus in alpha-synuclein aggregation. Neuroscience Letters. 323:2002;219-223.
234. McLean P.J., Kawamata H., Shariff S., Hewett J., Sharma N., Ueda K., et al. TorsinA and heat shock proteins act as molecular chaperones: suppression of α-synuclein aggregation. Journal of Neurochemistry. 83:2002;846-854.
235. McNaught K.S., Jenner P. Proteasomal function is impaired in substantia nigra in Parkinson's disease. Neuroscience Letters. 297:2001;191-194.
236. McNaught, K.St.P., Olanow, C.W., 2003. Proteolytic stress: a unifying concept for the etiopathogenesis of Parkinson's disease. Annals Neurology 53 (Supplement 3), S73-S86.
237. McNaught K.S., Olanow C.W., Halliwell B., Isacson O., Jenner P. Failure of the ubiquitin-proteasome system in Parkinson's disease. Nature Reviews Neuroscience. 2:2001;589-594.
238. McNaught K.S., Mytilineou C., Jnobaptiste R., Yabut J., Shashidharan P., Jennert P., et al. Impairment of the ubiquitin-proteasome system causes dopaminergic cell death and inclusion body formation in ventral mesencephalic cultures. Journal of Neurochemistry. 81:2002a;301-306.
239. McNaught K.S., Bjorklund L.M., Belizaire R., Isacson O., Jenner P., Olanow C.W. Proteasome inhibition causes nigral degeneration with inclusion bodies in rats. Neuroreport. 13:2002b;1437-1441.
240. McNaught K.S., Belizaire R., Isacson O., Jenner P., Olanow C.W. Altered proteasomal function in sporadic Parkinson's disease. Experimental Neurology. 179:2003;38-46.
241. Meredith G.E., Totterdell S., Petroske E., Santa Cruz K., Callison R.C., Lau Y.-S. Lysosomal malfunction accompanies alpha-synuclein aggregation in a progressive mouse model of Parkinson's disease. Brain Research. 956:2002;156-165.
242. Mezey E., Dehejia A.M., Harta G., Tresser N., Suchy S.F., Nussbaum R.L., et al. Alpha synuclein is present in Lewy bodies in sporadic Parkinson's disease. Molecular Psychiatry. 3:1998;493-499. (Published erratum appears in Molecular Psychiatry 1999 Mar;4(2), 197).
243. Mihm M.J., Jing L., Bauer J.A. Nitrotyrosine causes selective vascular endothelial dysfunction and DNA damage. Journal of Cardiovascular Pharmacology. 36:2000;182-187.
244. Mihm M.J., Schanbacher B.L., Wallace B.L., Wallace L.J., Uretsky N.J., Bauer J.A. Free 3-nitrotyrosine causes striatal neurodegeneration in vivo. Journal of Neuroscience. 21:(11):2001;RC149.
245. Mizuno Y., Hattori N., Kitada T., Matsumine H., Mori H., Shimura H., et al. Familial Parkinson's disease. alpha-Synuclein and parkin. Advances in Neurology. 86:2001;13-21.
246. Mizuta I., Nishimura M., Mizuta E., Yamasaki S., Ohta M., Kuno S. Meta-analysis of α-synuclein/NACP polymorphism in Parkinson's disease in Japan. Journal of Neurology Neurosurgery and Psychiatry. 73:2002;350.
247. Moran L.B., Kosel S., Spitzer C., Schwaiger F.W., Riess O., Kreutzberg G.W., et al. Expression of alpha-synuclein in non-apoptotic, slowly degenerating facial motoneurones. Journal of Neurocytology. 30:2001;515-521.
248. Mori F., Tanji K., Yoshimoto M., Takahashi H., Wakabayashi K. Demonstration of alpha-synuclein immunoreactivity in neuronal and glial cytoplasm in normal human brain tissue using proteinase K and formic acid pretreatment. Experimental Neurology. 176:2002;98-104.
249. Mori H., Kondo T., Yokochi M., Matsumine H., Nakagawa-Hattori Y., Miyake T., et al. Pathologic and biochemical studies of juvenile parkinsonism linked to chromosome 6q. Neurology. 51:1998;890-892.
250. Mouradian M.M. Recent advances in the genetics and pathogenesis of Parkinson disease. Neurology. 58:2002;179-185.
251. Muchowski P.J. Protein misfolding, amyloid formation, and neurodegeneration: a critical role for molecular chaperones? Neuron. 35:2002;9-12.
252. Murphy D.D., Rueter S.M., Trojanowski J.Q., Lee V.M. Synucleins are developmentally expressed, and alpha-synuclein regulates the size of the presynaptic vesicular pool in primary hippocampal neurons. Journal of Neuroscience. 20:2000;3214-3220.
253. Nakamura T., Tanaka T., Nagano T., Yoneda T., Takagi H., Sato M. Distribution of mRNA encoding Tat-binding protein-1 (TBP-1), a component of 26S proteasome, in the rat brain. Brain Research Molecular Brain Research. 53:1998;321-327.
254. Nakamura T., Yamashita H., Nagano Y., Takahashi T., Avraham S., Avraham H., et al. Activation of Pyk2/RAFTK induces tyrosine phosphorylation of alpha-synuclein via Src-family kinases. FEBS Letters. 521:2002;190-194.
255. Narhi L., Wood S.J., Steavenson S., Jiang Y., Wu G.M., Anafi D., et al. Both familial Parkinson's disease mutations accelerate alpha-synuclein aggregation. Journal of Biological Chemistry. 274:1999;9843-9846. (Published erratum appears in Journal of Biological Chemistry 1999 May 7;274(19):13728).
256. Nielsen M.S., Vorum H., Lindersson E., Jensen P.H. Ca2+ binding to alpha-synuclein regulates ligand binding and oligomerization. Journal of Biological Chemistry. 276:2001;22680-22684.
257. Nieuwenhuys R. The greater limbic system, the emotional motor system and the brain. Progress in Brain Research. 107:1996;551-580.
258. Neumann M., Kahle P.J., Giasson B.I., Ozmen L., Borroni E., Spooren W., et al. Misfolded proteinase K-resistant hyperphosphorylated α-synuclein in aged transgenic mice with locomotor deterioration and in human α-synucleinopathies. Journal of Clinical Investigation. 110:2002;1429-1439.
259. O'Dell T.J., Kandel E.R., Grant S.G. Long-term potentiation in the hippocampus is blocked by tyrosine kinase inhibitors. Nature. 353:1991;558-560.
260. O'Kelly I., Butler M.H., Zilberberg N., Goldstein S.A.N. Forward transport: 14-3-3 binding overcomes retention in endoplasmic reticulum by dibasic signals. Cell. 111:2002;577-588.
261. Okochi M., Walter J., Koyama A., Nakajo S., Baba M., Iwatsubo T., et al. Constitutive phosphorylation of the Parkinson's disease associated alpha-synuclein. Journal of Biological Chemistry. 275:2000;390-397.
262. Orlowski M., Wilk S. Catalytic activities of the 20 S proteasome, a multicatalytic proteinase complex. Archives of Biochemistry and Biophysics. 383:2000;1-16.
263. Ostrerova-Golts N., Petrucelli L., Hardy J., Lee J.M., Farer M., Wolozin B. The A53T alpha-synuclein mutation increases iron-dependent aggregation and toxicity. Journal of Neuroscience. 20:2000;6048-6054. (In process citation).
264. Ostrerova N., Petrucelli L., Farrer M., Mehta N., Choi P., Hardy J. alpha-Synuclein shares physical and functional homology with 14-3-3 proteins. Journal of Neuroscience. 19:1999;5782-5791.
265. Ozelius L.J., Hewett J.W., Page C.E., Bressman S.B., Kramer P.L., Shalish C., et al. The early-onset torsion dystonia gene (DYT1) encodes an ATP-binding protein. Nature Genetics. 1:1997;40-48.
266. Paik S.R., Lee J.H., Kim D.H., Chang C.S., Kim J. Aluminum-induced structural alterations of the precursor of the non-A beta component of Alzheimer's disease amyloid. Archives of Biochemistry and Biophysics. 344:1997;325-334.
267. Paik S.R., Shin H.J., Lee J.H., Chang C.S., Kim J. Copper(II)-induced self-oligomerization of alpha-synuclein. Biochemical Journal. 340:1999;821-828.
268. Paik S.R., Shin H.J., Lee J.H. Metal-catalyzed oxidation of alpha-synuclein in the presence of Copper(II) and hydrogen peroxide. Archives of Biochemistry and Biophysics. 378:2000;269-277.
269. Pan Z.Z., Bruening W., Giasson B.I., Lee V.M., Godwin A.K. gamma-Synuclein promotes cancer cell survival and inhibits stress- and chemotherapeutic drug-induced apoptosis by modulating MAPK pathways. Journal of Biological Chemistry. 277:2002;35050-35060.
270. Pang D.T., Wang J.K., Valtorta F., Benfenati F., Greengard P. Protein tyrosine phosphorylation in synaptic vesicles. Proceedings of the National Academy of Sciences of the United States of America. 85:1988;762-766.
271. Papay R., Zuscik M.J., Ross S.A., Yun J., McCune D.F., Gonzalez-Cagrera P., et al. Mice expressing the α1B-adrenergic receptor induces a synucleinopathy with excessive tyrosine nitration but decreased phosphorylation. Journal of Neurochemistry. 83:2002;623-634.
272. Park J.Y., Lansbury P.T. Beta-synuclein inhibits the formation of alpha-synuclein protofibrils: a possible therapeutic strategy against Parkinson's disease. Biochemistry. 42:2003;3696-3700.
273. Park B.W., O'Rourke D.M., Wang Q., Davis J.G., Post A., Qian X., et al. Induction of the Tat-binding protein 1 gene accompanies the disabling of oncogenic erbB receptor tyrosine kinases. Proceedings of the National Academy of Sciences of the United States of America. 96:1999;6434-6438.
274. Park S.M., Jung H.Y., Chung K.C., Rhim H., Park J.H., Kim J. Stress-induced aggregation profiles of GST-alpha-synuclein fusion proteins: role of the C-terminal acidic tail of alpha-synuclein in protein thermosolubility and stability. Biochemistry. 41:2002a;4137-4146.
275. Park S.U., Ferrer J.V., Javitch J.A., Kuhn D.M. Peroxynitrite inactivates the human dopamine transporter by modification of cysteine 342: potential mechanism of neurotoxicity in dopamine neurons. Journal of Neuroscience. 22:2002b;4399-4405.
276. Pastor P., Munoz E., Ezquerra M., Obach V., Marti M.J., Valldeoriola F., et al. Analysis of the coding and the 5′ flanking regions of the alpha-synuclein gene in patients with Parkinson's disease. Movement Disorder. 16:2001;1115-1119.
277. Pastor P., Ezquerra M., Tolosa E., Munoz E., Jose Marti M., Valldeoriola F., et al. Further extension of the H1 haplotype associated with progressive supranuclear palsy. Movement Disorder. 17:2002;550-556.
278. Paxinou E., Chen Q., Weisse M., Giasson B.I., Norris E.H., Rueter S.M., et al. Induction of alpha-synuclein aggregation by intracellular nitrative insult. Journal of Neuroscience. 21:2001;8053-8061.
279. Payton J.E., Perrin R.J., Clayton D.F., George J.M. Protein-protein interactions of alpha-synuclein in brain homogenates and transfected cells. Brain Research Molecular Brain Research. 95:2001;138-145.
280. Pendleton R.G., Parvez F., Sayed M., Hillman R. Effects of pharmacological agents upon a transgenic model of Parkinson's disease in Drosophila melanogaster. Journal of Pharmacology and Experimental Therapeutics. 300:2002;91-96.
281. Perez R.G., Waymire J.C., Lin E., Liu J.J., Guo F., Zigmond M.J. A role for alpha-synuclein in the regulation of dopamine biosynthesis. Journal of Neuroscience. 22:2002;3090-3099.
282. Perrin R.J., Woods W.S., Clayton D.F., George J.M. Interaction of human alpha-synuclein and Parkinson's disease variants with phospholipids. Structural analysis using site-directed mutagenesis. Journal of Biological Chemistry. 275:2000;34393-34398. (In process citation).
283. Perrin R.J., Woods W.S., Clayton D.F., George J.M. Exposure to long chain polyunsaturated fatty acids triggers rapid multimerization of synucleins. Journal of Biological Chemistry. 276:2001;41958-41962.
284. Petrucelli L., O'Farrell C., Lockhart P.J., Baptista M., Kehoe K., Vink L., et al. Parkin protects against the toxicity associated with mutant α-synuclein: proteasome dysfunction selectively affects catecholaminergic neurons. Neuron. 36:2002;1007-1019.
285. Perutz M.F., Pope B.J., Owen D., Wanker E.E., Scherzinger E. Aggregation of proteins with expanded glutamine and alanine repeats of the glutamine-rich and asparagine-rich domains of Sup35 and of the amyloid beta-peptide of amyloid plaques. Proceedings of the National Academy of Sciences of the United States of America. 99:2002;5596-5600.
286. Piao Y.S., Wakabayashi K., Hayashi S., Yoshimoto M., Takahashi H. Aggregation of (α-synuclein/NACP in the neuronal and glial cells in diffuse Lewy body disease: a survey of six patients. Clinical Neuropathology. 19:2000;163-169.
287. Piao Y.S., Hayashi S., Hasegawa M., Wakabayashi K., Yamada M., Yoshimoto M., et al. Co-localization of alpha-synuclein and phosphorylated tau in neuronal and glial cytoplasmic inclusions in a patient with multiple system atrophy of long duration. Acta Neuropathologica. 101:2001;285-293.
288. Pollanen M.S., Dickson D.W., Bergeron C. Pathology and biology of the Lewy body. Journal of Neuropathology and Experimental Neurology. 52:1993;183-191.
289. Polymeropoulos M.H., Lavedan C., Leroy E., Ide S.E., Dehejia A., Dutra A., et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science. 276:1997;2045-2047. (See comments).
290. Pong K., Doctrow S.R., Baudry M. Prevention of 1-methyl-4-phenylpyridinium- and 6-hydroxydopamine-induced nitration of tyrosine hydroxylase and neurotoxicity by EUK-134, a superoxide dismutase and catalase mimetic, in cultured dopaminergic neurons. Brain Research. 881:2000;182-189.
291. Power J.H.T., Shannon J.M., Blumbergs P.C., Gai W.-P. Nonselenium glutathione peroxidase in human brain. Elevated levels in Parkinson's disease and dementia with Lewy bodies. American Journal of Pathology. 161:2002;885-894.
292. Pronin A.N., Morris A.J., Surguchov A., Benovic J.L. Synucleins are a novel class of substrates for G protein-coupled receptor kinases. Journal of Biological Chemistry. 275:2000;26515-26522.
293. Rathke-Hartlieb S., Kahle P.J., Neumann M., Ozmen L., Haid S., Okochi M., et al. Sensitivity to MPTP is not increased in Parkinson's disease-associated mutant alpha-synuclein transgenic mice. Journal of Neurochemistry. 77:2001;1181-1184.
294. Ribeiro C.S., Carneiro K., Ross C.A., Menezes J.R., Engelender S. Synphilin-1 is developmentally localized to synaptic terminals and its association with synaptic vesicles is modulated by alpha-synuclein. Journal of Biological Chemistry. 277:2002;23927-23933.
295. Richfield E.K., Thiruchelvam M.J., Cory-Slechta D.A., Wuertzer C., Gainetdinov R.R., Caron M.G., et al. Behavioral and neurochemical effects of wild-type and mutated human alpha-synuclein in transgenic mice. Experimental Neurology. 175:2002;35-48.
296. Rideout H.J., Larsen K.E., Sulzer D., Stefanis L. Proteasomal inhibition leads to formation of ubiquitin/alpha-synuclein-immunoreactive inclusions in PC12 cells. Journal of Neurochemistry. 78:2001;899-908.
297. Rideout H.J., Stefanis L. Proteasomal inhibition-induced inclusion formation and death incortical neurons require transcription and ubiquitination. Molecular and Cellular Neuroscience. 21:2002;223-238.
298. Rochet J.C., Conway K.A., Lansbury P.T.J. Inhibition of fibrillization and accumulation of prefibrillar oligomers in mixtures of human and mouse alpha-synuclein. Biochemistry. 39:2000;10619-10626.
299. Rockenstein E., Hansen L.A., Mallory M., Trojanowski J.Q., Galasko D., Masliah E. Altered expression of the synuclein family mRNA in Lewy body and Alzheimer's disease. Brain Research. 914:2001;48-56.
300. Ross O.A., Awayn N.H., McWhinney D., Maxwell L.D., El-Agnaf O.M., Barnett Y.A., et al. A novel polymorphic triplet repeat in intron five of the alpha-synuclein gene: no evidence of expansion or allelic association with idiopathic Parkinson's disease in the Irish. Neuroreport. 13:2002;1621-1625.
301. Rub U., Del T.K., Schultz C., Ghebremedhin E., de V.R., Jansen S.E., et al. Parkinson's disease: the thalamic components of the limbic loop are severely impaired by alpha-synuclein immunopositive inclusion body pathology. Neurobiology of Aging. 23:2002;245-254.
302. Saha A.R., Ninkina N.N., Hanger D.P., Anderton B.H., Davies A.M., Buchman V.L. Induction of neuronal death by alpha-synuclein. European Journal of Neuroscience. 12:2000;3073-3077.
303. Saito Y., Kawai M., Inoue K., Sasaki R., Arai H., Nanba E., et al. Widespread expression of alpha-synuclein and tau immunoreactivity in Hallervorden-Spatz syndrome with protracted clinical course. Journal of the Neurological Sciences. 177:2000;48-59.
304. Salter M.W. Src, N-methyl-D-aspartate (NMDA) receptors, and synaptic plasticity. Biochemical Pharmacology. 56:1998;789-798.
305. Sasaki K., Doh-Ura K., Wakisaka Y., Iwaki T. Clusterin/apolipoprotein J is associated with cortical Lewy bodies: immunohistochemical study in cases with alpha-synucleinopathies. Acta Neuropathologica (Berlin). 104:2002;225-230.
306. Satoh J., Kuroda Y. alpha-Synuclein expression is up-regulated in NTera2 cells during neuronal differentiation but unaffected by exposure to cytokines and neurotrophic factors. Parkinsonism and Related Disorders. 8:2001;7-17.
307. Sawamoto N., Honda M., Hanakawa T., Fukuyama H., Shibasaki H. Cognitive slowing in Parkinson's disease: a behavioral evaluation independent of motor slowing. Journal of Neuroscience. 22:2002;5198-5203.
308. Schlossmacher M.G., Frosch M.P., Gai W.P., Medina M., Sharma N., Forno L., et al. Parkin localizes to the Lewy bodies of Parkinson disease and dementia with Lewy bodies. American Journal of Pathology. 160:2002;1655-1667.
309. Schmidt M.L., Martin J.A., Lee V.M., Trojanowski J.Q. Covergence of Lewy bodies and neurofibrillary tangles in amygdala neurons of Alzheimer's disease and Lewy body disorders. Acta Neuropathologica (Berlin). 91:1996;475-481.
310. Scott W.K., Nance M.A., Watts R.L., Hubble J.P., Koller W.C., Lyons K., et al. Complete genomic screen in Parkinson disease: evidence for multiple genes. Journal of the American Medical Association. 286:2002;2239-2244.
311. Seo J.-H., Rah J.-C., Choi S.H., Shin J.K., Min K., Kim H.-S. α-Synuclein regulates neuronal survival via Bcl-2 family expression and Pi3/Akt kinase pathway. FASEB Journal. 16:2002;1826-1828.
312. Serpell L.C., Berriman J., Jakes R., Goedert M., Crowther R.A. Fiber diffraction of synthetic alpha-synuclein filaments shows amyloid-like cross-beta conformation. Proceedings of the National Academy of Sciences of the United States of America. 97:2000;4897-4902.
313. Sharma N., Hewett J., Ozelius L.J., Ramesh V., McLean P.J., Breakefield X.O., et al. A close association of torsinA and alpha-synuclein in Lewy bodies: a fluorescence resonance energy transfer study. American Journal of Pathology. 159:2001;339-344.
314. Sharon R., Goldberg M.S., Bar-Josef I., Betensky R.A., Shen J., Selkoe D.J. alpha-Synuclein occurs in lipid-rich high molecular weight complexes, binds fatty acids, and shows homology to the fatty acid-binding proteins. Proceedings of the National Academy of Sciences of the United States of America. 98:2001;9110-9115.
315. Sharon R., Bar-Joseph I., Frosch M.P., Walsh D.M., Hamilton J.A.,
316. Shashidharan P., Good P.F., Hsu A., Perl D.P., Brin M.F., Olanow C.W. TorsinA accumulation in Lewy bodies in sporadic Parkinson's disease. Brain Research. 877:2002;379-381.
317. Sherer T.B., Betarbet R., Stout A.K., Lund S., Baptista M., Panov A.V., et al. An in vitro model of Parkinson's disease: linking mitochondrial impairment to altered alpha-synuclein metabolism and oxidative damage. Journal of Neuroscience. 22:2002;7006-7015.
318. Sherer T.B., Kim J.H., Betarbet R., Greenamyre J.T. Subcutaneous rotenone exposure causes highly selective dopaminergic degeneration and alpha-synuclein aggregation. Experimental Neurology. 179:2003;9-16.
319. Sherman M.Y., Goldberg A.L. Cellular defenses against unfolded proteins: a cell biologist thinks about neurodegenerative diseases. Neuron. 29:2001;15-32.
320. Shih S.C., Sloper-Mould K.E., Hicke L. Monoubiquitin carries a novel internalization signal that is appended to activated receptors. EMBO Journal. 19:2000;187-198.
321. Shimura H., Schlossmacher M.G., Hattori N., Frosch M.P., Trockenbacher A., Schneider R., et al. Ubiquitination of a new form of alpha-synuclein by parkin from human brain: implications for Parkinson's disease. Science. 293:2001;263-269.
322. Shringarpure R., Grune T., Mehlhase J., Davies K.J. Ubiquitin-conjugation is not required for the degradation of oxidized proteins by the proteasome. Journal of Biological Chemistry. 278:2002;311-318.
323. Shtilerman M.D., Ding T.T., Lansbury P.T.J. Molecular crowding accelerates fibrillization of alpha-synuclein: could an increase in the cytoplasmic protein concentration induce Parkinson's disease? Biochemistry. 41:2002;3855-3860.
324. Siddiqui M.F., Rast S., Lynn M.J., Auchus A.P., Pfeiffer R.F. Autonomic dysfunction in Parkinson's disease: a comprehensive symptom survey. Parkinsonism and Related Disorders. 8:2002;277-284.
325. Snyder H., Mensah K., Theisler C., Lee J.M., Matouschek, Wolozin B. Aggregated and monomeric α-synuclein bind to the S6′ proteasomal protein and inhibit proteasomal function. Journal of Biological Chemistry. 278:2003;11753-11759.
326. Sobel N., Thomason M.E., Stappen I., Tanner C.M., Tetrud J.W., Bower J.M., et al. An impairment in sniffing contributes to the olfactory impairment in Parkinson's disease. Proceedings of the National Academy of Sciences of the United States of America. 98:2001;4154-4159.
327. Sollars V., Lu X., Xiao L., Wang X., Garfinkel M.D., Ruden D.M. Evidence for an epigenetic mechanism by which Hsp90 acts as a capacitator for morphological evolution. Nature Genetics. 33:2003;70-74.
328. Song et al., 2002. Society Neuroscience, 32, 226.1.
329. Souza J.M., Giasson B.I., Lee V.M., Ischiropoulos H. Chaperone-like activity of synucleins. FEBS Letters. 474:2000a;116-119.
330. Souza J.M., Giasson B.I., Chen Q., Lee V.M., Ischiropoulos H. Dityrosine cross-linking promotes formation of stable alpha-synuclein polymers. Implication of nitrative and oxidative stress in the pathogenesis of neurodegenerative synucleinopathies. Journal of Biological Chemistry. 275:2000b;18344-18349.
331. Specht C.G., Schoepfer R. Deletion of the alpha-synuclein locus in a subpopulation of C57BL/6J inbred mice. BMC Neuroscience. 2:2001;11.
332. Spillantini M.G., Schmidt M.L., Lee V.M., Trojanowski J.Q., Jakes R., Goedert M. alpha-Synuclein in Lewy bodies. Nature. 388:1997;839-840.
333. Spillantini M.G., Crowther R.A., Jakes R., Cairns N.J., Lantos P.L., Goedert M. Filamentous alpha-synuclein inclusions link multiple system atrophy with Parkinson's disease and dementia with Lewy bodies. Neuroscience Letters. 251:1998a;205-208.
334. Spillantini M.G., Crowther R.A., Jakes R., Hasegawa M., Goedert M. alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies. Proceedings of the National Academy of Sciences of the United States of America. 95:1998b;6469-6473.
335. Spillantini M.G., Goedert M.G. Tau and Parkinson disease. Journal of American Medical Association. 286:2001;2324-2326.
336. Stefanis L., Larsen K.E., Rideout H.J., Sulzer D., Greene L.A. Expression of A53T mutant but not wild-type alpha-synuclein in PC12 cells induces alterations of the ubiquitin-dependent degradation system, loss of dopamine release, and autophagic cell death. Journal of Neuroscience. 21:2001;9549-9560.
337. Stefanova N., Seppi K., Scherfler C., Puschban Z., Wenning G.K. Depression in alpha-synucleinopathies: prevalence, pathophysiology and treatment. Journal Neural Transmission Supplement. 60:2000;335-343.
338. Stefanova N., Klimaschewski L., Poewe W., Wenning G.K., Reindl M. Glial cell death induced by overexpression of alpha-synuclein. Journal of Neuroscience Research. 65:2001;432-438.
339. Stefanova N., Emgard M., Klimaschewski L., Wenning G.K., Reindl M. Ultrastructure of alpha-synuclein-positive aggregations in U373 astrocytoma and rat primary glial cells. Neuroscience Letters. 323:2002;37-40.
340. Strickland E., Hakala K., Thomas P.J., DeMartino G.N. Recognition of misfolding proteins by PA700, the regulatory subcomplex of the 26 S proteasome. Journal of Biological Chemistry. 275:2000;5565-5572.
341. Stumptner C., Heid H., Fuchsbichler A., Hauser H., Mischinger H.J., Zatloukal K., et al. Analysis of intracytoplasmic hyaline bodies in a hepatocellular carcinoma. Demonstration of p62 as major constituent. American Journal of Pathology. 154:1999;1701-1710.
342. Sung J.Y., Kim J., Paik S.R., Park J.H., Ahn Y.S., Chung K.C. Induction of neuronal cell death by Rab5A-dependent endocytosis of alpha-synuclein. Journal of Biological Chemistry. 276:2001;27441-27448.
343. Surguchov A., Surgucheva I., Solessio E., Baehr W. Synoretin - a new protein belonging to the synuclein family. Molecular and Cellular Neuroscience. 13:1999;95-103.
344. Swerdlow R.H., Parks J.K., Cassarino D.S., Binder D.R., Bennett J.P., Di Iorio G., et al. Biochemical analysis of cybrids expressing mitochondrial DNA from Contoursi kindred Parkinson's subjects. Experimental Neurology. 169:2001;479-485.
345. Tabrizi S.J., Orth M., Wilkinson J.M., Taanman J.W., Warner T.T., Cooper J.M., et al. Expression of mutant alpha-synuclein causes increased susceptibility to dopamine toxicity. Human Molecular Genetics. 9:2000;2683-2689.
346. Takahashi H., Ohama E., Suzuki S., Horikawa Y., Ishikawa A., Morita T., et al. Familial juvenile Parkinsonism: clinical and pathologic study in a family. Neurology. 44:1994;437-441.
347. Takahashi H., Wakabayashi K. The cellular pathology of Parkinson's disease. Neuropathology. 21:2001;315-322.
348. Takahashi M., Iseki E., Kosaka K. Cyclin-dependent kinase 5 (Cdk5) associated with Lewy bodies in diffuse Lewy body disease. Brain Research. 862:2000;253-256.
349. Takahashi T., Yamashita H., Nakamura T., Nagano Y., Nakamura S. Tyrosine 125 of alpha-synuclein plays a critical role for dimerization following nitrative stress. Brain Research. 938:2002a;73-80.
350. Takahashi M., Kanuka H., Fujiwara H., Koyama A., Hasegawa M., Miura M., et al. Phosphorylation of α-synuclein characteristic of synucleinopathy lesions is recapitulated in α-synuclein transgenic Drosophila. Neuroscience Letters. 336:2002b;155-158.
351. Takeda A., Mallory M., Sundsmo M., Honer W., Hansen L., Masliah E. Abnormal accumulation of NACP/alpha-synuclein in neurodegenerative disorders. American Journal of Pathology. 152:1998;367-372.
352. Takenouchi T., Hashimoto M., Hsu L.J., Mackowski B., Rockenstein E., Mallory M., et al. Reduced neurite outgrowth and cell adhesion in neuronal cells transfected with human α-synuclein. Molecular and Cellular Neuroscience. 17:2001;141-150.
353. Tamo W., Imaizumi T., Tanji K., Yoshida H., Mori F., Yoshimoto M., et al. Expression of alpha-synuclein, the precursor of non-amyloid beta component of Alzheimer's disease amyloid, in human cerebral blood vessels. Neuroscience Letters. 326:2002;5-8.
354. Tan E.K., Matsuura T., Nagamitsu S., Khajavi M., Jankovic J., Ashizawa T. Polymorphism of NACP-Rep1 in Parkinson's disease: an etiologic link with essential tremor? Neurology. 54:2000;1195-1198.
355. Tan E.K., Tan C., Shen H., Chai A., Lum S.Y., Teoh M.L., et al. alpha-Syncuclein promoter and risk of Parkinson's disease: microsatellite and allelic size variability. Neuroscience Letters. 336:2003;70-72.
356. Tanaka Y., Engelender S., Igarashi S., Rao R.K., Wanner T., Tanzi R.E., et al. Inducible expression of mutant alpha-synuclein decreases proteasome activity and increases sensitivity to mitochondria-dependent apoptosis. Human Molecular Genetics. 10:2001;919-926.
357. Tanji K., Imaizumi T., Yoshida H., Mori F., Yoshimoto M., Satoh K., et al. Expression of alpha-synuclein in a human glioma cell line and its upregulation by interleukin-1beta. Neuroreport. 12:2001;1909-1912.
358. Tanji K., Mori F., Imaizumi T., Yoshida H., Matsumiya T., Tamo W., et al. Upregulation of alpha-synuclein by lipopolysaccharide and interleukin-1 in human macrophages. Pathology International. 52:2002;572-577.
359. Thiruchelvam M., Richfield E.K., Baggs R.B., Tank A.W., Cory-Slechta D.A. The nigrostriatal dopaminergic system as a preferential target of repeated exposures to combined paraquat and maneb: implications for Parkinson's disease. Journal of Neuroscience. 20:2000;9207-9214.
360. Tofaris G.K., Layfield R., Spillantini M.G. alpha-Synuclein metabolism and aggregation is linked to ubiquitin-independent degradation by the proteasome. FEBS Letters. 509:2001;22-26.
361. Togo T., Iseki E., Marui W., Akiyama H., Ueda K., Kosaka K. Glial involvement in the degeneration process of Lewy body-bearing neurons and the degredation process of Lewy bodies in brains of dementia with Lewy bodies. Journal of the Neurological Sciences. 184:2001;71-75.
362. Torres G.E., Yao W.D., Mohn A.R., Quan H., Kim K.M., Levey A.I., et al. Functional interaction between monoamine plasma membrane transporters and the synaptic PDZ domain-containing protein PICK1. Neuron. 30:2001;121-134.
363. Touchman J.W., Dehejia A., Chiba-Falek O., Cabin D.E., Schwartz J.R., Orrison B.M., et al. Human and mouse alpha-synuclein genes: comparative genomic sequence analysis and identification of a novel gene regulatory element. Genome Research. 11:2001;78-86.
364. Trimmer et al., 2002. Society Neuroscience, 32, 485.7.
365. Ueda K., Fukushima H., Masliah E., Xia Y., Iwai A., Yoshimoto M., et al. Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease. Proceedings of the National Academy of Sciences of the United States of America. 90:1993;11282-11286.
366. Uhl A., Berg D., Holzmann C., Kruger R., Berger K., Arzberger T., et al. 14-3-3 is a component of Lewy bodies in Parkinson's disease - mutation analysis and association studies of 14-3-3 eta. Brain Research. 108:2002;33-39.
367. Uversky V.N., Fink A.L. Amino acid determinants of alpha-synuclein aggregation: putting together pieces of the puzzle. FEBS Letters. 522:2002;9-13.
368. Uversky V.N., Li J., Fink A.L. Evidence for a partially folded intermediate in alpha-synuclein fibril formation. Journal of Biological Chemistry. 276:2001a;10737-10744.
369. Uversky V.N., Lee H.J., Li J., Fink A.L., Lee S.J. Stabilization of partially folded conformation during alpha-synuclein oligomerization in both purified and cytosolic preparations. Journal of Biological Chemistry. 276:2001b;43495-43498.
370. Uversky V.N., Li J., Fink A.L. Trimethylamine-N-oxide-induced folding of alpha-synuclein. FEBS Letters. 509:2001c;31-35.
371. Uversky V.N., Li J., Fink A.L. Metal-triggered structural transformations, aggregation, and fibrillation of human alpha-synuclein. A possible molecular NK between Parkinson's disease and heavy metal exposure. Journal of Biological Chemistry. 276:2001d;44284-44296.
372. Uversky V.N., Li J., Fink A.L. Pesticides directly accelerate the rate of alpha-synuclein fibril formation: a possible factor in Parkinson's disease. FEBS Letters. 500:2001e;105-108.
373. Uversky V.N., Yamin G., Souillac P.O., Goers J., Glaser C.B., Fink A.L. Methionine oxidation inhibits fibrillation of human alpha-synuclein in vitro. FEBS Letters. 517:2002a;239-244.
374. Uversky V.N., Cooper M., Bower K.S., Li J., Fink A.L. Accelerated alpha-synuclein fibrillation in crowded milieu. FEBS Letters. 515:2002b;99-103.
375. Uversky V.N., Li J., Souillac P., Millett I.S., Doniach S., Jakes R., et al. Biophysical properties of the synucleins and their propensities to fibrillate. Journal of Biological Chemistry. 277:2002c;11970-11978.
376. Valente E.M., Bentivoglio A.R., Dixon P.H., Ferraris A., Ialongo T., Frontali M., et al. Localization of a novel locus for autosomal recessive early-onset Parkinsonism, PARK6, on human chromosome 1p35-p36. American Journal of Human Genetics. 68:2001;895-900.
377. van der Putten H., Wiederhold K.-H., Probst A., Barbieri S., Mistl C., Danner S., et al. Neuropathology in mice expressing human α-synuclein. Journal of Neuroscience. 20:2000;6021-6029.
378. Varkonyi J., Rosenbaum H., Baumann N., MacKenzie J.J., Simon Z., Aharon-Peretz J., et al. Gaucher disease associated with parkinsonism: four further case reports. American Journal of Medical Genetics A. 116:2003;348-351.
379. Vila M., Vukosavic S., Jackson-Lewis V., Neystat M., Jakowec M., Przedborski S. alpha-Synuclein up-regulation in substantia nigra dopaminergic neurons following administration of the parkinsonian toxin MPTP. Journal of Neurochemistry. 74:2000;721-729.
380. Volles M.J., Lansbury P.T.J. Vesicle permeabilization by protofibrillar alpha-synuclein is sensitive to Parkinson's disease-linked mutations and occurs by a pore-like mechanism. Biochemistry. 41:2002;4595-4602.
381. Volles M.J., Lee S.J., Rochet J.C., Shtilerman M.D., Ding T.T., Kessler J.C., Lansbury P.T. Vesicle permeabilization by protofibrillar alpha-synuclein: implications for the pathogenesis and treatment of Parkinson's disease. Biochemistry. 40:2001;7812-7819.
382. Wakabayashi K., Matsumoto K., Takayama K., Yoshimoto M., Takahashi H. NACP, a presynaptic protein, immunoreactivity in Lewy bodies in Parkinson's disease. Neuroscience Letters. 239:1997;45-48.
383. Wakabayashi K., Engelender S., Yoshimoto M., Tsuji S., Ross C.A., Takahashi H. Synphilin-1 is present in Lewy bodies in Parkinson's disease. Annals of Neurology. 47:2000;521-523.
384. Wakabayashi K., Engelender S., Tanaka Y., Yoshimoto M., Mori F., Tsuji S., et al. Immunocytochemical localization of synphilin-1, an alpha-synuclein-associated protein, in neurodegenerative disorders. Acta Neuropathologica (Berlin). 103:2002;209-214.
385. Walsh D.M., Lomakin A., Benedek G.B., Condron M.M., Teplow D.B. Amyloid beta-protein fibrillogenesis. Detection of a protofibrillar intermediate. Journal of Biological Chemistry. 272:1997;22364-22372.
386. Walsh D.M., Hartley D.M., Kusumoto Y., Fezoui Y., Condron M.M., Lomakin A., et al. Amyloid beta-protein fibrillogenesis. Structure and biological activity of protofibrillar intermediates. Journal of Biological Chemistry. 274:1999;25945-25952.
387. Walsh D.M., Klyubin I., Fadeeva J.V., Cullen W.K., Anwyl R., Wolfe M.S., et al. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature. 416:2002;535-539.
388. Weinreb P.H., Zhen W., Poon A.W., Conway K.A., Lansbury P.T.J. NACP, a protein implicated in Alzheimer's disease and learning, is natively unfolded. Biochemistry. 35:1996;13709-13715.
389. Wilson S.M., Bhattacharyya B., Rachel R.A., Coppola V., Tessarollo L., Householder D.B., et al. Synaptic defects in ataxia mice result from a mutation in Usp14, encoding a ubiquitin-specific protease. Nature Genetics. 32:2002;420-425.
390. Windisch M., Hutter-Paier B., Rockenstein E., Hashimoto M., Mallory M., Masliah E. Development of a new treatment for Alzheimer's disease and Parkinson's disease using anti-aggregatory beta-synuclein-derived peptides. Journal of Molecular Neuroscience. 19:2002;63-69.
391. Wirths O., Weickert S., Majtenyi K., Havas L., Kahle P.J., Okochi M., et al. Lewy body variant of Alzheimer's disease: alpha-synuclein in dystrophic neurites of A beta plaques. Neuroreport. 11:2000;3737-3741.
392. Wood S.J., Wypych J., Steavenson S., Louis J.C., Citron M., Biere A.L. alpha-Synuclein fibrillogenesis is nucleation-dependent. Implications for the pathogenesis of Parkinson's disease. Journal of Biological Chemistry. 274:1999;19509-19512.
393. Xia Y., Saitoh T., Ueda K., Tanaka S., Chen X., Hashimoto M., et al. Characterization of the human alpha-synuclein gene: genomic structure, transcription start site, promoter region and polymorphisms. Journal of Alzheimer's Disease. 3:2001;485-494.
394. Xu J., Kao S.Y., Lee F.J., Song W., Jin L.W., Yankner B.A. Dopamine-dependent neurotoxicity of alpha-synuclein: a mechanism for selective neurodegeneration in Parkinson disease. Nature Medicine. 8:2002;600-606.
395. Yaffe M.B. How do 14-3-3 proteins work? - Gatekeeper phosphorylation and the molecular anvil hypothesis. FEBS Letters. 513:2002;53-57.
396. Yamazaki M., Arai Y., Baba M., Iwatsubo T., Mori O., Katayama Y., et al. alpha-Synuclein inclusions in amygdala in the brains of patients with the parkinsonism-dementia complex of Guam. Journal of Neuropathology and Experimental Neurology. 59:2000;585-591.
397. Yokota O., Terada S., Ishizu H., Tsuchiya K., Kitamura Y., Ikeda K., et al. NACP/α-synuclein immunoreactivity in diffuse neurofibrillary tangles with calcification (DNTC). Acta Neuropathologica. 104:2002;333-341.
398. Yoshimoto M., Iwai A., Kang D., Otero D.A., Xia Y., Saitoh T. NACP, the precursor protein of the non-amyloid beta/A4 protein (A beta) component of Alzheimer disease amyloid, binds A beta and stimulates A beta aggregation. Proceedings of the National Academy of Sciences of the United States of America. 92:1995;9141-9145.
399. Zeng B.Y., Dass B., Owen A., Rose S., Cannizzaro C., Tel B.C., et al. 6-Hydroxydopamine lesioning differentially affects alpha-synuclein mRNA expression in the nucleus accumbens, striatum and substantia nigra of adult rats. Neuroscience Letters. 322:2002;33-36.
400. Zhang Y., Gao J., Chung K.K., Huang H., Dawson V.L., Dawson T.M. Parkin functions as an E2-dependent ubiquitin-protein ligase and promotes the degradation of the synaptic vesicle-associated protein, CDCrel-1. Proceedings of the National Academy of Sciences of the United States of America. 97:2000;13354-13359.
401. Zhao W., Cavallaro S., Gusev P., Alkon D.L. Nonreceptor tyrosine protein kinase pp60c-src in spatial learning: synapse-specific changes in its gene expression, tyrosine phosphorylation, and protein-protein interactions. Proceedings of the National Academy of Sciences of the United States of America. 97:2000;8098-8103.
402. Zhou W., Schaack J., Zawada W.M., Freed C.R. Overexpression of human alpha-synuclein causes dopamine neuron death in primary human mesencephalic culture. Brain Research. 926:2002;42-50.
403. Zhu, M., Fink, A.L. Lipid binding inhibits alpha-synuclein fibril formation. Journal of Biological Chemistry, in press.